Dow Jones Top Company Headlines at 1 PM ET: David Ellison Asks CNN CEO to Stay After Paramount-Warner Deal Closes | OpenAI ...

Dow Jones
Oct 02

David Ellison Asks CNN CEO to Stay After Paramount-Warner Deal Closes

Bari Weiss isn't expected to have a role involving CNN at close of the deal, people familiar with Ellison's thinking said.

----

OpenAI Parts Ways With Researchers Who Allegedly Shared Confidential Information

The AI startup is in the throes of responding to several incidents in which its AI models went rogue.

----

General Motors Third-Quarter Vehicle Sales Fall 5.5%

Discontinued models and a diminished market for electric vehicles weighed on the automaker's performance in the third quarter.

----

Boeing's Engineers Hold Leverage in Contract Showdown

Stung by a mechanics strike in 2024, the plane maker is trying to avoid a new work stoppage with its engineers and technicians.

----

McCormick Is Working to Win Over Value-Conscious Shoppers

The spice maker still reported a 17% increase in sales during the latest quarter, largely due to its acquisition of a controlling interest in McCormick de Mexico earlier this year. On an organic basis, sales ticked up 1.9%.

----

UBS Shareholder Calls for Bank to Leave Switzerland

U.S. investor Artisan Partners has urged the bank to part ways with its home country over new capital rules.

----

Keurig Dr Pepper Hires Kimberly-Clark President Torres to Helm Coffee Spinoff

Keurig Dr Pepper has hired Russ Torres as chief executive of its coffee spinoff, plucking the executive from Kimberly-Clark.

----

Accenture Stock Climbs as AI Demand Boosts Results

The consulting company posted fourth-quarter profit of $1.99 billion, or $3.29 a share, compared with $1.41 billion, or $2.25 a share, a year earlier.

----

Apple's Biggest Battleground for Foldable Phones Is China

Huawei and other Chinese competitors reported higher demand for foldables after announcement of the iPhone Duo.

----

Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal

The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.

----

Foghorn Stock Craters as Lilly Scraps Cancer Deal, Forcing 40% Layoffs

Foghorn Therapeutics and Eli Lilly don't plan any future collaborations following the dissolution of a cancer-drug partnership.

----

A Cancer Test Has Investors Betting Big. But Will Insurers Pay?

An FDA panel backed Grail's Galleri test. But the Medicare money the business depends on is far from guaranteed.

----

Tech CEOs Privately Questioned Amodei for Sounding AI Alarm Bells

Nvidia CEO Jensen Huang was among the executives at Tuesday's White House event who called out the Anthropic leader for his warnings about the technology's capabilities.

----

Arla Foods to Invest Millions to Tap Protein-Rich Dairy Demand, CEO Says

The Denmark dairy giant will invest more than €63 million, or about $71 million, to expand capacity at existing skyr and cottage cheese production sites in Germany and Sweden.

----

Lynas Rare Earths to Buy Meteoric Resources in $672 Million Deal

The deal gives Lynas a foothold in Brazil's growing rare-earths industry and comes amid a race to rebuild rare-earths production outside China.

 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10